Beam Therapeutics (BEAM) Gains from Sales and Divestitures (2020 - 2025)
Beam Therapeutics (BEAM) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $1.0 million as the latest value for Q4 2025.
- Quarterly Gains from Sales and Divestitures fell 19.46% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 19.46% year-over-year, with the annual reading at $1.0 million for FY2025, 19.46% down from the prior year.
- Gains from Sales and Divestitures for Q4 2025 was $1.0 million at Beam Therapeutics, up from $783939.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $1.3 million in Q4 2024, with the low at $283186.0 in Q1 2022.
- Average Gains from Sales and Divestitures over 5 years is $583177.8, with a median of $481075.0 recorded in 2023.
- The sharpest move saw Gains from Sales and Divestitures tumbled 58.44% in 2022, then skyrocketed 177.31% in 2024.
- Over 5 years, Gains from Sales and Divestitures stood at $1.0 million in 2021, then plummeted by 58.44% to $424303.0 in 2022, then increased by 10.66% to $469531.0 in 2023, then surged by 177.31% to $1.3 million in 2024, then decreased by 19.46% to $1.0 million in 2025.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $1.0 million, $783939.0, and $688359.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.